DOCSLIB.ORG

Penetration of Topically Applied Betamethasone Sodium Phosphate Into Human Aqueous Humour

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Penetration of Topically Applied Betamethasone Sodium Phosphate Into Human Aqueous Humour Eye (1990) 4, 603-606 Penetration of Topically Applied Betamethasone Sodium Phosphate into Human Aqueous Humour D. G. WATSON,* C. N. 1. McGHEE,*t 1. M. MIDGLEY,* G. N. DUTTON,t M. 1. NOBLEt Glasgow Summary Gas Chromatography combined with Negative Chemical Ionisation Mass Spec­ trometry (GCMS) was used to determine the absorption of topically applied beta­ methasone sodium phosphate into the aqueous humour of human subjects undergoing routine intraocular surgery. The Betamethasone concentration was greatest in the interval 91-120 minutes following topical administration (mean peak concentration = 7.7 ng/ml). At twelve hours post instillation the mean concentration of Betamethasone was 2.5 ng/ml and detectable levels were recorded in the aqueous humour 24 hours after application (mean concentration 0.4 ng/ml). The authors have previously reported data on commonly used, commercially available, the penetration of dexamethasone alcohol topical corticosteroid preparations. 0.1%,1 prednisolone sodium phosphate 0.5%2 and prednisolone acetate 1.0%3 into Subjects and methods human aqueous humour utilising the highly Patients who were scheduled to undergo rou­ sensitive and specific technique of Gas Chro­ tine cataract surgery were recruited to the matography with Negative Chemical Ionisa­ study and informed consent was obtained in tion Mass Spectrometry (GCMS)." Limited all cases. Patients with corneal disease or data is available on the direct measurement of inflammatory ocular conditions which might Betamethasone in aqueous humour of animal affect steroid penetration into the eye were models' following topical application. We excluded from the study. None of the patients used GCMS to analyse the penetration of had been prescribed topical or systemic ste­ betamethasone sodium phosphate into the roids in the six months prior to surgery. Sixty­ aqueous humour at varying times following six eyes of 66 patients were included. The the topical application of eyedrops to human mean age of patients included was 72 years volunteer subjects undergoing routine catar­ (range 56-92 years). act extraction. This work forms part of a Fifty microlitres of betamethasone sodium larger ongoing study which aims to establish phosphate (0.1%) solution (Betnesol: Glaxo the aqueous humour pharmacokinetics of the Ltd, UK) were introduced by micropipette * Department of Pharmacy, Division of Pharmaceutical Chemistry, University of Strathc1yde, Royal College Buildings, 204 George Street, Glasgow GIIXW. t Department of Ophthalmology, Southern General Hospital, ' Govan Road, Glasgow. :j: Tennent Institute of Ophthalmology, University of Glasgow, Western Infirmary, Glasgow G 11 6NT. Correspondence to: Dr C. N. J. McGhee, Senior Registrar, Tennent Institute of Ophthalmology, Western Infirmary, Glasgow G 11 6NT. 604 D. G. WATSON ET AL. Table I Mean concentration (nglml) (± standard trideuterated compound added before extrac­ error of mean) of betamethasone in human aqueous tion. Thus the deuterated isotopomer of beta­ humour at various times (min) following the topical methasone co-chroma to graphed with the administration of betamethasone sodium phosphate corresponding undeuterated substance and 0.1%. yielded ions in its mass spectrum equivalent to Time No. of Mean conc'n in those obtained from the undeuterated com­ interval eyes aqueous humour pound together with a mass increment of 2-3 (mins) (n=66) (ng/ml) ± (SEM) atomic mass units. This technique is suitable for the quantification of betamethasone in the 0-30 5 0.0 ± 0.0 0.1-10 ng range. 31--60 13 3.8 ± 1.0 61-90 9 4.2 ± 0.6 In order to detect if betamethasone sodium 91-120 10 7.7 ± 1.8 phospate was present in the aqueous humour 121-180 11 6.5 ± 1.5 ten samples were incubated with acid phos­ 181-240 2 6.9 ± 1.1 phatase following the initial extraction with 241-460 2 5.3 ± 2.1 ethyl acetate (acid phosphatase was found to 461-760 5 2.5 ± 0.6 761-1060 4 0.7 ± 0.5 be effective in releasing betamethasone from 1061-1430 5 0.4 ± 0.2 its phosphate in standard solutions). The enzymatically treated solution was then pro­ into the lower conjunctival fornix of the eye cessed as described above for the untreated aqueous humour. No additional betametha­ being prepared for surgery at varied times up sone could be detected after treatment with to 24 hours pre-operatively. Two drops each acid phosphatase. of Phenylephrine 10% and Cyclopentolate 1% were administered one hour prior to sur­ Results gery to obtain mydriasis. The concentrations of betamethasone in Tw enty-nine of the operations were per­ human aqueous humour at varied time inter­ formed under general anaesthesia and 37 vals following the topical administration of were performed under retrobulbar anaes­ Betamethasone Sodium Phosphate are shown thesia. 0.05 to 0.15 millilitres of aqueous in Table I. The concentrations of betametha­ humour were aspirated with a tuberculin sone in aqueous humour vs time from instill­ syringe through a 25 gauge needle after a par­ ation is shown in Figure 1. Peak mean 91- tial thickness corneoscleral incision had been concentrations were recorded between 120 made but before the anterior chamber had minutes after application. Levels which 30% been entered. The interval between the are approximately of the peak drug con­ instillation of betamethasone sodium phos­ centration were measured between eight and 12 24 phate and the aspiration of aqueous humour hours and trace levels were recorded at was noted. The aqueous samples were hours. immediately frozen and stored at -20°C until Concentration ng/ml analysed by GCMS. Two nanograms of deuterated betametha­ 9 sone (containing largely the trideuterated 7 derivative) were added to the sample of aque­ ous humour (which had previously been 5 diluted to 1 ml with high purity water). The aqueous layer was extracted with ethyl ace­ 3 tate (2 xI ml) and the extract chemically treated to give the di-methoxime tris-trimeth­ 4 ylsilyl ether derivative. The derivatised o 200 400 600 800 1000 1200 extract was then subjected to GCMS in the Time (minutes) negative chemical ionisation mode; the Fig. 1. Mean peak concentrations of betamethaspne undeuterated corticosteroid present in the (nglml ± SEM) in human aqueous humour vs time aqueous humour was identified and quanti­ (mins) following topical application of betamethasone fiedwith reference to the known amount of dil sodium phosphate 0.1%. PENETRATION OF TOPICALLY APPLIED BETAMETHASONE SODIUM PHOSPHATE 605 There were no statistical differences in sitive technique. The remit of our study was to aqueous betamethasone concentrations when analyse the intraocular penetration of com­ the results from patients receiving general mercially available topical corticosteroids, anaesthetic were compared to those who had therefore, our data is limited to the 0.1% con­ undergone retrobulbar anaesthesia. centration of betamethasone sodium phos­ phate. None the less it is worth noting that Discussion previous animal studies have shown that beta­ In human aqueous humour the mean peak methasone sodium phosphate, prednisolone concentration of betamethasone (7.7 ng/ml) sodium phosphate, and prednisolone acetate is much lower than we have previously all achieve significantly higher aqueous levels 1.0% recorded for dexamethasone alcohol 0.1% when delivered in preparations when (31.0 ng/ml),1 prednisolone sodium phos­ compared to lower concentrations.5,11,12 phate 0.5% (25.6 ng/ml)2 or prednisolone ace­ Among the possible variables we found no tate 1.0% (669.6 ng/ml)3. However, the mean significant differences in aqueous levels of betamethasone when patients were grouped concentration of betamethasone does not fall by age, sex, or type of anaesthetic. It might be below 68% of the peak concentration within postulated that eyes with cataract do not eight hours of application, whereas, the peak behave identically to inflamed eyes, in which levels of the other three drugs fall to less than intraocular inflammation can interfere with 33% of peak concentration at eight hours. the epithelial barrier to a water soluble The lower mean peak concentration of beta­ corticosteroid,13 or that the application of methasone when compared to dexametha­ cyclopentolate and phenylephrine might sone and prednisolone acetate might be partly influencethe surface characteristics of the eye explained by its preparation as a phosphate; and therefore the penetration of topical ste­ such corticosteroid preparations have been roids. Unfortunately, these are variables shown to be polar and thus the intact corneal which are unavoidable in human research; the epithelium presents more of a barrier to their former we cannot influencethe latter we hope penetration than the more lipid soluble ace­ has been minimised by the standardisation of tate and alcohol corticosteroid derivatives.6,7,8 preoperative mydriatic doses. In such comparisons it is important to remem­ Although betame.thasone sodium phos­ ber that on a weight for weight basis dexame­ phate 0.1 % does not reach the mean peak thasone and betamethasone have a five to aqueous concentrations of dexamethasone seven fold greater systemic anti-inflammatory alcohol 0.1%, prednisolone sodium phos­ activity than prednisolone.9 However, it has phate 0.5% or prednisolone acetate 1.0% it been suggested on the basis of evidence from does have a longer aqueous half life. There­ animal models that these differences in fore topical application two to three times systemic anti-inflammatory activity may not daily may be sufficient to maintain peak beta­ 0 be directly extrapolated to the ocular milieu. 1 methasone concentrations in the aqueous To the authors' knowledge there are no pre­ humour. However, we have yet to analyse the viously published data on betamethasone additive effects of repeat application and as concentrations in human aqueous humour such the aqueous kinetics of the cortico­ following topical administration. However, steroids examined so far cannot be fully pre­ betamethasone has been studied in rabbit dicted. Hopefully when this data is available eyes following topical administration using more rational regimens may be applied for the radioimmunoassay techniques.
Load more

Recommended publications
  • Docetaxel with Prednisone Or Prednisolone for the Treatment of Prostate Cancer ISSN 1366-5278 Feedback Your Views About This Report
    Health Technology Assessment Health Technology Health Technology Assessment 2007; Vol. 11: No. 2 2007; 11: No. 2 Vol. Docetaxel with prednisone or prednisolone for the treatment of prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Feedback The HTA Programme and the authors would like to know R Collins, E Fenwick, R Trowman, R Perard, your views about this report. The Correspondence Page on the HTA website G Norman, K Light, A Birtle, S Palmer (http://www.hta.ac.uk) is a convenient way to publish and R Riemsma your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website. We look forward to hearing from you. January 2007 The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, Health Technology Assessment University of Southampton, NHS R&D HTA Programme Southampton, SO16 7PX, UK. HTA Fax: +44 (0) 23 8059 5639 Email: [email protected] www.hta.ac.uk http://www.hta.ac.uk ISSN 1366-5278 HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents.
    [Show full text]
  • Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial Colin M
    Prednisolone Versus Dexamethasone for Croup: a Randomized Controlled Trial Colin M. Parker, MBChB, DCH, MRCPCH, FACEM,a,b Matthew N. Cooper, BCA, BSc, PhDc OBJECTIVES: The use of either prednisolone or low-dose dexamethasone in the treatment of abstract childhood croup lacks a rigorous evidence base despite widespread use. In this study, we compare dexamethasone at 0.6 mg/kg with both low-dose dexamethasone at 0.15 mg/kg and prednisolone at 1 mg/kg. METHODS: Prospective, double-blind, noninferiority randomized controlled trial based in 1 tertiary pediatric emergency department and 1 urban district emergency department in Perth, Western Australia. Inclusions were age .6 months, maximum weight 20 kg, contactable by telephone, and English-speaking caregivers. Exclusion criteria were known prednisolone or dexamethasone allergy, immunosuppressive disease or treatment, steroid therapy or enrollment in the study within the previous 14 days, and a high clinical suspicion of an alternative diagnosis. A total of 1252 participants were enrolled and randomly assigned to receive dexamethasone (0.6 mg/kg; n = 410), low-dose dexamethasone (0.15 mg/kg; n = 410), or prednisolone (1 mg/kg; n = 411). Primary outcome measures included Westley Croup Score 1-hour after treatment and unscheduled medical re-attendance during the 7 days after treatment. RESULTS: Mean Westley Croup Score at baseline was 1.4 for dexamethasone, 1.5 for low-dose dexamethasone, and 1.5 for prednisolone. Adjusted difference in scores at 1 hour, compared with dexamethasone, was 0.03 (95% confidence interval 20.09 to 0.15) for low-dose dexamethasone and 0.05 (95% confidence interval 20.07 to 0.17) for prednisolone.
    [Show full text]
  • Penetration of Synthetic Corticosteroids Into Human Aqueous Humour
    Eye (1990) 4, 526--530 Penetration of Synthetic Corticosteroids into Human Aqueous Humour C. N. 1. McGHEE,1.3 D. G. WATSON, 3 1. M. MIDGLEY, 3 M. 1. NOBLE, 2 G. N. DUTTON, z A. I. FERNl Glasgow Summary The penetration of prednisolone acetate (1%) and fluorometholone alcohol (0.1%) into human aqueous humour following topical application was determined using the very sensitive and specific technique of Gas Chromatography with Mass Spec­ trometry (GCMS). Prednisolone acetate afforded peak mean concentrations of 669.9 ng/ml within two hours and levels of 28.6 ng/ml in aqueous humour were detected almost 24 hours post application. The peak aqueous humour level of flu­ orometholone was S.lng/ml. The results are compared and contrasted with the absorption of dexamethasone alcohol (0.1%), betamethasone sodium phosphate (0.1 %) and prednisolone sodium phosphate (0.5%) into human aqueous humour. Topical corticosteroid preparations have been prednisolone acetate (1.0%) and fluorometh­ used widely in ophthalmology since the early alone alcohol (0.1 %) (preliminary results) 1960s and over the last 10 years the choice of into the aqueous humour of patients under­ preparations has become larger and more going elective cataract surgery. varied. Unfortunately, data on the intraocular penetration of these steroids in humans has SUbjects and Methods not paralleled the expansion in the number of Patients who were scheduled to undergo rou­ available preparations; indeed until recently, tine cataract surgery were recruited to the estimation of intraocular penetration has study and informed consent was obtained in been reliant upon extrapolation of data from all cases (n=88), Patients with corneal disease animal models (see Watson et ai., 1988, for or inflammatory ocular conditions which bibliography).
    [Show full text]
  • Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids
    Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. K B Horwitz, L D Horwitz J Clin Invest. 1982;69(4):750-758. https://doi.org/10.1172/JCI110513. Research Article Sex differences and steroid hormones are known to influence the vascular system as shown by the different incidence of atherosclerosis in men and premenopausal women, or by the increased risk of cardiovascular diseases in women taking birth control pills or men taking estrogens. However, the mechanisms for these effects in vascular tissues are not known. Since steroid actions in target tissues are mediated by receptors, we have looked for cytoplasmic steroid receptor proteins in vascular tissues of dogs. We find specific saturable receptors, sedimenting at 8S on sucrose density gradients for estrogens (measured with [3H]estradiol +/- unlabeled diethylstilbestrol), androgens (measured with [3H]R1881 +/- unlabeled R1881 and triamcinolone acetonide), and glucocorticoids (measured with [3H]dexamethasone +/- unlabeled dexamethasone); they are absent for progesterone (measured with [3H]R5020 +/- unlabeled R5020 and dihydrotestosterone). Progesterone receptors can, however, be induced by 1-wk treatment of dogs with physiological estradiol concentrations (100 pg/ml serum estrogen), indicating a functional estrogen receptor. Receptor levels range from 20 to 2,000 fmol/mg DNA. They are specific for each hormone; unrelated steroids fail to complete for binding. Low dissociation constants, measured by Scatchard analyses, show that binding is of high affinity. Steroid binding sites are in the media and/or adventitia since they persist when the intima is removed. Compared with the arteries, receptor levels are reduced 80% in inferior venae cavae of […] Find the latest version: https://jci.me/110513/pdf Canine Vascular Tissues Are Targets for Androgens, Estrogens, Progestins, and Glucocorticoids KATHRYN B.
    [Show full text]
  • Dexamethasone Inhibits the Induction of NAD+-Dependent 15
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1497 (2000) 61^68 www.elsevier.com/locate/bba Dexamethasone inhibits the induction of NAD-dependent 15-hydroxyprostaglandin dehydrogenase by phorbol ester in human promonocytic U937 cells Min Tong 1, Hsin-Hsiung Tai * Division of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082, USA Received 29 December 1999; received in revised form 2 March 2000; accepted 9 March 2000 Abstract Pro-inflammatory prostaglandins are known to be first catabolized by NAD-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) to inactive metabolites. This enzyme is under regulatory control by various inflammation-related agents. Regulation of this enzyme was investigated in human promonocytic U937 cells. 15-PGDH activity was found to be optimally induced by phorbol 12-myristate 13-acetate (PMA) at 10 nM after 24 h of treatment. The induction was blocked by staurosporine or GF 109203X indicating that the induction was mediated by protein kinase C. The induction by PMA was inhibited by the concurrent addition of dexamethasone. Nearly complete inhibition was observed at 50 nM. Other glucocorticoids, such as hydrocortisone and corticosterone, but not sex hormones, were also inhibitory. Inhibition by dexamethasone could be reversed by the concurrent addition of antagonist mifepristone (RU-486) indicating that the inhibition was a receptor-mediated event. Either induction by PMA or inhibition by dexamethasone the 15-PGDH activity correlated well with the enzyme protein expression as shown by the Western blot analysis. These results provide the first evidence that prostaglandin catabolism is regulated by glucocorticoids at the therapeutic level.
    [Show full text]
  • Dexamethasone in Patients with Acute Lung Injury from Acute Monocytic Leukaemia
    Eur Respir J 2012; 39: 648–653 DOI: 10.1183/09031936.00057711 CopyrightßERS 2012 Dexamethasone in patients with acute lung injury from acute monocytic leukaemia E´. Azoulay*, E. Canet*, E. Raffoux#, E. Lengline´#, V. Lemiale*, F. Vincent*, A. de Labarthe#, A. Seguin*, N. Boissel#, H. Dombret# and B. Schlemmer* ABSTRACT: The use of steroids is not required in myeloid malignancies and remains AFFILIATIONS controversial in patients with acute lung injury (ALI) or acute respiratory distress syndrome *Medical ICU and #Hematology Dept, Saint-Louis (ARDS). We sought to evaluate dexamethasone in patients with ALI/ARDS caused by acute Hospital, Paris, France. monocytic leukaemia (AML FAB-M5) via either leukostasis or leukaemic infiltration. Dexamethasone (10 mg every 6 h until neutropenia) was added to chemotherapy and intensive CORRESPONDENCE ´ care unit (ICU) management in 20 consecutive patients between 2005 and 2008, whose data were E. Azoulay AP-HP compared with those from 20 historical controls (1994–2002). ICU mortality was the primary Hoˆpital Saint-Louis criterion. We also compared respiratory deterioration rates, need for ventilation and nosocomial Medical ICU infections. 75010 Paris 17 (85%) patients had hyperleukocytosis, 19 (95%) had leukaemic masses, and all 20 had France E-mail: [email protected] severe pancytopenia. All patients presented with respiratory symptoms and pulmonary infiltrates paris.fr prior to AML FAB-M5 diagnosis. Compared with historical controls, dexamethasone-treated patients had a significantly lower ICU mortality rate (20% versus 50%; p50.04) and a trend for less Received: respiratory deterioration (50% versus 80%; p50.07). There were no significant increases in the May 24 2011 Accepted after revision: rates of infections with dexamethasone.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • Corticosteroids in Terminal Cancer-A Prospective Analysis of Current Practice
    Postgraduate Medical Journal (November 1983) 59, 702-706 Postgrad Med J: first published as 10.1136/pgmj.59.697.702 on 1 November 1983. Downloaded from Corticosteroids in terminal cancer-a prospective analysis of current practice G. W. HANKS* T. TRUEMAN B.Sc., M.B., B.S., M.R.C.P.(U.K.) S.R.N. R. G. TWYCROSS M.A., D.M., F.R.C.P. Sir Michael Sobell House, The Churchill Hospital, Headington, Oxford OX3 7LJ Summary Introduction Over half of a group of 373 inpatients with advanced Corticosteroids have a major role to play in the malignant disease were treated with corticosteroids control of symptoms in patients with advanced for a variety of reasons. They received either pred- malignant disease. They may be employed in a non- nisolone or dexamethasone, or replacement therapy specific way to improve mood and appetite; or they with cortisone acetate. Forty percent of those receiv- may be indicated as specific adjunctive therapy in the ing corticosteroids benefited from them. A higher relief of symptoms related to a large tumour mass or response rate was seen when corticosteroids were to nerve compression. The management of a numberProtected by copyright. prescribed for nerve compression pain, for raised of other symptoms and syndromes may also be intracranial pressure, and when used in conjunction facilitated by treatment with corticosteroids (Table with chemotherapy. No significant difference in 1). efficacy was noted between the 2 drugs. The results, The use of corticosteroids in patients with ad- however, suggest that with a larger sample, dexame- vanced cancer is empirical, as it is in other non- thasone would have been shown to be significantly endocrine indications.
    [Show full text]
  • Dexamethasone and Fludrocortisone Inhibit Hedgehog Signaling In
    This is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes. Article Cite This: ACS Omega 2018, 3, 12019−12025 http://pubs.acs.org/journal/acsodf Dexamethasone and Fludrocortisone Inhibit Hedgehog Signaling in Embryonic Cells † ‡ † ‡ Kirti Kandhwal Chahal,*, , Milind Parle, and Ruben Abagyan*, † Department of Pharmaceutical Sciences, G. J. University of Science and Technology, Hisar 125001, India ‡ Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92037, United States ABSTRACT: The hedgehog (Hh) pathway plays a central role in the development and repair of our bodies. Therefore, dysregulation of the Hh pathway is responsible for many developmental diseases and cancers. Basal cell carcinoma and medulloblastoma have well- established links to the Hh pathway, as well as many other cancers with Hh-dysregulated subtypes. A smoothened (SMO) receptor plays a central role in regulating the Hh signaling in the cells. However, the complexities of the receptor structural mechanism of action and other pathway members make it difficult to find Hh pathway inhibitors efficient in a wide range. Recent crystal structure of SMO with cholesterol indicates that it may be a natural ligand for SMO activation. Structural similarity of fluorinated corticosterone derivatives to cholesterol motivated us to study the effect of dexamethasone, fludrocortisone, and corticosterone on the Hh pathway activity. We identified an inhibitory effect of these three drugs on the Hh pathway using a functional assay in NIH3T3 glioma response element cells. Studies using BODIPY-cyclopamine and 20(S)-hydroxy cholesterol [20(S)-OHC] as competitors for the transmembrane (TM) and extracellular cysteine-rich domain (CRD) binding sites showed a non-competitive effect and suggested an alternative or allosteric binding site for the three drugs.
    [Show full text]
  • Ketoconazole Revisited: a Preoperative Or Postoperative Treatment in Cushing's Disease
    European Journal of Endocrinology (2008) 158 91–99 ISSN 0804-4643 CLINICAL STUDY Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease F Castinetti, I Morange, P Jaquet, B Conte-Devolx and T Brue Department of Endocrinology, Diabetes, Metabolic Diseases and Nutrition, Hoˆpital de la Timone, Centre Hospitalier Universitaire de Marseille and Faculte´ de Me´decine, Universite´ de la Me´diterrane´e, 264 rue St Pierre, Cedex 5, 13385 Marseille, France (Correspondence should be addressed to T Brue; Email: [email protected]) Abstract Context: Although transsphenoidal surgery remains the first-line treatment in Cushing’s disease (CD), recurrence is observed in about 20% of cases. Adjunctive treatments each have specific drawbacks. Despite its inhibitory effects on steroidogenesis, the antifungal drug ketoconazole was only evaluated in series with few patients and/or short-term follow-up. Objective: Analysis of long-term hormonal effects and tolerance of ketoconazole in CD. Design: A total of 38 patients were retrospectively studied with a mean follow-up of 23 months (6–72). Setting: All patients were treated at the same Department of Endocrinology in Marseille, France. Patients: The 38 patients with CD, of whom 17 had previous transsphenoidal surgery. Intervention: Ketoconazole was begun at 200–400 mg/day and titrated up to 1200 mg/day until biochemical remission. Main outcome measures: Patients were considered controlled if 24-h urinary free cortisol was normalized. Results: Five patients stopped ketoconazole during the first week because of clinical or biological intolerance. On an intention to treat basis, 45% of the patients were controlled as were 51% of those treated long term.
    [Show full text]
  • 18-Dehydrogenase Deficiency W
    Arch Dis Child: first published as 10.1136/adc.51.8.576 on 1 August 1976. Downloaded from Archives of Disease in Childhood, 1976, 51, 576. Hypoaldosteronism in three sibs due to 18-dehydrogenase deficiency W. HAMILTON, A. E. McCANDLESS, J. T. IRELAND, and C. E. GRAY From the University Departments of Child Health, Liverpool and Glasgow Hamilton, W., McCandless, A. E., Ireland, J. T., and Gray, C. E. (1976). Archives of Disease in Childhood, 51, 576. Hypoaldosteronism in three sibs due to 18-dehydrogenase deficiency. Three sibs all presented in the early neonatal period with a salt-losing syndrome. The salt-losing form of congenital adrenal hyperplasia was diagnosed and appropriate treatment with glucocorticosteroids, mineralocorticosteroids, and additional dietary salt started. Although early life was maintained with difficulty, with age all3 children required decreasingamounts ofreplace- ment steroids to maintain normal plasma electrolyte balance. They were reinvestigated at the ages of 15 years and 8 years (twins), when cortisol synthesis and metabolism proved normal, but aldosterone synthesis was blocked by deficiency of 18-dehydro- genase. Rational treatment of these cases of a salt-losing syndrome in which aldo- sterone synthesis alone is blocked due to lack of the enzyme 18-dehydrogenase requires the administration of a mineralocorticosteroid drug only. Since deoxycor- ticosterone (acetate or pivalate) requires intramuscular administration, as life-long therapy oral fludrocortisone is preferable. Although fludrocortisone has glucocorti- coid activity, the 'hydrocortisone equivalent' effect of the small dosage used was un- likely to inhibit either pituitary corticotrophin or growth hormone production. Salt-loss of adrenal origin is recognized as a female external genitalia or macrogenitosomia http://adc.bmj.com/ feature of 3/1-hydroxysteroid dehydrogenase de- praecox in the male.
    [Show full text]
  • Summary of Product Characteristics
    Prednisolone, DK/H/2488/001-006, March 2021 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT /…/ 2.5 mg tablets /…/ 5 mg tablets /…/ 10 mg tablets /…/ 20 mg tablets /…/ 25 mg tablets /…/ 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2.5 mg prednisolone. Each tablet contains 5 mg prednisolone. Each tablet contains 10 mg prednisolone. Each tablet contains 20 mg prednisolone. Each tablet contains 25 mg prednisolone. Each tablet contains 30 mg prednisolone. Excipient with known effect: Each 2.5 mg tablet contains 89.2 mg of lactose monohydrate Each 5 mg tablet contains 87.2 mg of lactose monohydrate Each 10 mg tablet contains 81.7 mg of lactose monohydrate Each 20 mg tablet contains 163.4 mg of lactose monohydrate Each 25 mg tablet contains 159.4 mg of lactose monohydrate Each 30 mg tablet contains 153.4 mg of lactose monohydrate For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablets 2.5mg tablet Yellow, 7mm, round, flat, tablet, with a score line on one side, imprinted with “A610” on one side and “2.5” on the other. 5mg tablet White, 7mm, round, flat, tablet, with a score line on one side, imprinted with “A620” on one side and “5” on the other. 10mg tablet Red, 7mm, round, flat, tablet, with a score line on one side, imprinted with “A630” on one side and “10” on the other. 20mg tablet Red, 9mm, round, flat, tablet, with a score line on one side, imprinted with “A640” on one side and “20” on the other.
    [Show full text]